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Aim: To examine the medium-term stability of anthropometric and cardio-metabolic 
parameters in the general population. Materials & methods: Participants were 5160 
men and women from the English Longitudinal Study of Ageing (age ≥50 years) 
assessed in 2004 and 2008. Anthropometric data included height, weight, BMI and 
waist circumference. Cardio-metabolic parameters included blood pressure, serum 
lipids (total cholesterol, HDL, LDL, triglycerides), hemoglobin, fasting glucose, 
fibrinogen and C-reactive protein. Results: Stability of anthropometric variables was 
high (all intraclass correlations >0.92), although mean values changed slightly (-0.01 
kg weight, +1.33 cm waist). Cardio-metabolic parameters showed more variation: 
correlations ranged from 0.43 (glucose) to 0.81 (HDL). The majority of participants 
(71–97%) remained in the same grouping relative to established clinical cut-offs. 
Conclusion: Over a 4-year period, anthropometric and cardio-metabolic parameters 
showed good stability. These findings suggest that when no means to obtain more 
recent data exist, a one-time sample will give a reasonable approximation to average 
levels over the medium-term, although reliability is reduced.
Keywords:  anthropometric • cardio-metabolic • reliability • reproducibility • stability  
• variability
Anthropometric variables such as BMI and 
waist circumference have been established 
as valuable indicators for risk of chronic dis-
eases (e.g., cardiovascular disease, diabetes, 
cancer)  [1–6]. Cardio-metabolic parameters 
such as cholesterol, fibrinogen, CRP and fast-
ing glucose are also strongly associated with 
some of these chronic diseases [7–11].
As the evidence for the clinical importance 
of anthropometric and cardio-metabolic 
markers has emerged, many epidemiological 
studies have incorporated them in their data 
sets. However, measurements are often taken 
at only one time due to financial or logistical 
restrictions. This leaves many data sets with 
restricted availability of up-to-date measure-
ments when examining links with disease 
outcomes. The value of the biomarker data 
in these studies therefore depends on how 
reliably they capture average ‘exposure’ over 
time.
Several cardio-metabolic parameters, 
including CRP and glycated hemoglobin, 
have been shown to be relatively stable over 
short periods (days or weeks) in healthy vol-
unteers [12–17], although diurnal fluctuations 
may have been overlooked by drawing sam-
ples at the same time of day. Other parame-
ters, particularly related to lipids (e.g., triglyc-
erides, LDL cholesterol), appear to fluctuate, 
at least at levels above a certain threshold 
[13,18–20]. Less is known about stability in the 
general population, which would inevitably 
include people who are not entirely healthy. 
Studies of stability over longer assessment 
intervals have typically been in small samples 
or restricted to analysis of a single cardio-
metabolic parameter [21–38], which might be 
due to the high costs associated with obtain-
ing samples or practical difficulties related to 
organizing an investigation of this nature. 
None have explicitly compared healthy indi-
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viduals with those who have existing conditions where 
variability might be higher.
In this study, we examined the stability of anthro-
pometric and cardio-metabolic parameters in a large 
cohort of older adults (≥50 years) living in England 
over a 4-year period. Analyses were run on both the 
full sample and a healthy subsample.
Materials & methods
Participants & procedures
The data for these analyses are from the English Lon-
gitudinal Study of Ageing (ELSA), an ongoing pro-
spective cohort study representative of older men and 
women living in England. The sampling and methods 
used in ELSA have been described in detail elsewhere 
[39]. Briefly, ELSA is a panel study recruited from 
households responding to the Health Survey for Eng-
land [40] in 1998, 1999 and 2001. All households with 
one or more members aged ≥50 years in 2002 were eli-
gible; around 19,924 individuals. Of this group, 2596 
individuals had died or were ineligible for follow-up by 
the onset of ELSA. Of the remainder, 12,099 (70%) 
became ELSA participants.
ELSA participants take part in biennial assessments. 
At each wave, participants are visited in their homes by 
trained interviewers to complete a computer-assisted 
personal interview, a self-administered questionnaire, 
and tests of cognitive function and walking speed. On 
alternate waves (every 4 years), nurses make home visits 
to collect objective measures of health status, including 
anthropometric measures, measures of physical func-
tion and blood tests from which to assay a range of 
biomarkers. Waves 2 and 4 (collected 2004–2005 and 
2008–2009) form the baseline and follow-up exami-
nations for the present analyses. Wave 2 was completed 
by 7666 participants, of whom 5745 also completed 
wave 4. Of these, 5160 participants provided data on 
at least one cardio-metabolic parameter at both time 
points, and formed the final analytical sample.
ELSA has received approval from various eth-
ics committees, including the London Multi-Centre 
Research Ethics Committee. Full informed consent 
has been obtained from all participants. The consent 
booklet for nurse visits is available at [41].
Measures
Demographic variables
Interviewers collected demographic information 
including age, sex, ethnicity and marital status. For the 
purpose of the present analyses, age was dichotomized 
at the mean (<65 years vs ≥65 years), ethnicity as white 
vs non-white, and marital status as married (including 
living as married) vs unmarried (single/never married, 
separated, divorced or widowed).
Anthropometric measures
Height was measured to the nearest millimeter using 
a portable stadiometer and weight to the nearest 0.1 
kg using Tanita THD-305 portable electronic scales. 
Waist circumference, defined as the midpoint between 
the lowest rib and the upper margin of the iliac crest, 
was measured to the nearest even millimeter. The nurse 
recorded any factors that could have compromised the 
reliability of anthropometric measurements, such as the 
participant being stooped, not keeping still during the 
measurements, or being unable or unwilling to remove 
shoes. Anthropometric data judged by the nurse to be 
unreliable were excluded from analyses of those vari-
ables. Aside from refusal, reasons for height and weight 
measurements not being taken included factors such 
as the participant being unsteady, unable to stand 
upright, chair-bound, confined to bed, or otherwise ill 
or in pain, and factors related to the equipment, such 
as the scales not working or the stadiometer not being 
available. BMI was calculated for all   participants with 
valid weight and height measurements.
Biological measures
We selected ten cardio-metabolic biomarkers that are 
established as indicators of chronic disease and had 
been measured at both waves: systolic blood pressure, 
diastolic blood pressure, total cholesterol, HDL cho-
lesterol, LDL cholesterol, triglycerides, fasting glucose, 
hemoglobin, fibrinogen and CRP.
Blood pressure was measured using the Omron 
HEM-907 blood pressure monitor, after participants 
were seated for at least 5 min. Three readings were 
taken at 1-min intervals. The first was discarded and 
the mean of the second and third used.
All participants who gave consent were eligible 
for blood samples to be taken, excluding those who 
reported clotting or bleeding disorders, history of fits 
or convulsions, or those on anti-coagulant medication. 
Viable blood samples were obtained from 4133 partici-
pants (80%) at baseline and 3880 participants (75%) 
at follow-up. Unless participants were over 80 years of 
age, had diabetes, reported ever having had a fit, were 
frail, or seemed unwell, where possible blood samples 
were obtained under fasting conditions, defined as 
having had no food or drink (except water) for at least 
5 h prior to the blood test. Fasting blood samples were 
obtained from 2595 participants (50%) at baseline and 
2261 participants (44%) at follow-up.
The protocol for the collection of the clinical mea-
surements and the blood samples can be found at [42]. 
Baseline and follow-up samples were analyzed at the 
Royal Victoria Infirmary laboratory in Newcastle upon 
Tyne (UK). Detailed information on the analyses and 
internal and external quality control protocols can be www.futuremedicine.com 111 future science group
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found in the 2004 Health Survey for England tech-
nical report [43], since the Health Survey for England 
and ELSA employed the same laboratory and the same 
guidelines and protocols for the blood analysis. Briefly, 
cholesterol levels were determined using the DAX 
Oxidase assay. Triglycerides were measured using an 
enzymatic assay on an Olympus 640 analyzer. Plasma 
glucose (in fasting samples only) was measured using 
the Hexokinase method. Hemoglobin was measured 
using two Abbott Diagnostics CELL-DYN 4000 ana-
lyzers. Fibrinogen was analyzed using a modification 
of the Clauss thrombin clotting method on the Orga-
non Teknika MDA-180 analyzer, with a CV of less 
than 10%. CRP was analyzed using the N Latex CRP 
mono-immunoassay on the Behring Nephelometer II 
analyzer.
Health-related variables
Presence of a long-standing illness was assessed with 
the question: “Do you have any long-standing illness, dis-
ability or infirmity? By long-standing I mean anything 
that has troubled you over a period of time or that is likely 
to affect you over a period of time.” If a positive response 
was given to the first question, the participant was also 
asked: “Does this illness or disability limit your activi-
ties in any way?” Affirmation of any form of limitation 
classified the participant as having a limiting long-
standing illness.
Interviewers also recorded whether participants 
were currently taking anti-hypertensive medication, 
injecting insulin for diabetes, or taking action to lower 
cholesterol. At baseline (wave 2), the latter was assessed 
using two questions: “Has any doctor talked to you about 
how to lower your cholesterol? This would include chang-
ing your diet, losing weight, getting more exercise or 
taking medication”; if yes: “Have you done any of these 
things to lower your cholesterol?” At follow-up (wave 4), 
participants were asked whether they were currently 
taking medication to lower cholesterol.
Statistical analysis
Four health-related variables that were thought likely 
to influence the cardio-metabolic parameters were 
used to distinguish a ‘healthy’ subsample from the 
full sample: limiting long-standing illness, anti-hyper-
tensive medication, injecting insulin for diabetes, and 
taking action to reduce cholesterol. We excluded from 
the healthy subsample all participants who reported a 
limiting long-standing illness at either wave or had a 
change in medication use for hypertension or diabe-
tes. We had intended to exclude those with a change 
in use of cholesterol-lowering medication, but because 
this was assessed differently at baseline (following 
doctor-recommended action) and follow-up (medica-
tion use) it was not possible to determine whether there 
had been a change in use of medication. Therefore, all 
participants reporting action to reduce cholesterol at 
either wave, not just those with a change in status, were 
excluded from the healthy subsample. Also excluded 
were those whose status on any of these four variables 
was unknown at either baseline or follow-up. All anal-
yses were conducted on both the full sample of eligible 
participants and the healthy subsample.
All analyses used SPSS version 21. In order to adjust 
for multiple comparisons, we considered a two-sided 
p-value < 0.01 statistically significant for each analy-
sis. Repeated-measures analyses of variance (ANO-
VAs) were used to examine significant mean shifts 
in each parameter, taking into account age and sex. 
Non-normally distributed variables (triglycerides, glu-
cose and CRP) were log-transformed for analyses to 
normalize skewed distributions. Geometric means and 
95% CIs are presented for log-transformed variables. 
The intraclass correlation coefficients (ICC) between 
baseline and follow-up values were computed for each 
anthropometric and cardio-metabolic parameter using 
the formula:
We also calculated the proportion of values remain-
ing consistently above or below the established cut-off 
for each cardio-metabolic parameter at the two time 
points. The cut-offs for total, LDL and HDL choles-
terol and triglycerides were obtained from the third 
report of the National Cholesterol Education Program 
expert panel on detection, evaluation and treatment 
of high blood cholesterol in adults [44], with choles-
terol values converted from mmol/l to mg/dl for these 
analyses. Cut-offs for blood pressure, fasting glucose 
and CRP were also obtained from statements by expert 
panels [45–47], and the cut-off for hemoglobin from two 
large studies of variability in hemoglobin levels [48,49]. 
In the absence of an established cut-off for fibrinogen, 
we used the upper quartile in the full eligible sample at 
baseline (3.6 g/l) to define high fibrinogen levels, as has 
been done in previous studies [50].
Finally, we re-estimated the associations between 
baseline and follow-up measurements controlling for 
attenuation due to measurement error and short-term 
intra-individual variability using the method recom-
mended by Nunnally & Bernstein [51], as detailed by 
Krueger & Schkade [52]. We applied the formula 
where x = baseline measurement; y = follow-up mea-
surement; ρxy = the true correlation between x and y; rxy 
ICC
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= the observed correlation between x and y; rxx = reli-
ability of x; and ryy = reliability of y. Intra-measure 
reliability (rxx and ryy) for anthropometric variables 
was based on reliability data from a sample of doctors 
trained in taking anthropometric measurements [53]. 
Estimates of reliability for cardio-metabolic param-
eters were based on findings of a number of d  ifferent 
studies [12–13,15,54–57].
Results
Baseline data were collected from 7666 individu-
als in 2004–2005, of whom 5160 individuals also 
provided data on at least one outcome at follow-up 
(2008–2009) and were therefore eligible for inclusion 
in these analyses. Compared to the 2506 individuals 
who were ineligible for inclusion, the analyzed sample 
(n = 5160) included more younger (51% vs 38%, p < 
0.001), female (56% vs 53%, p = 0.028), and married 
participants (67% vs 64%, p = 0.003), but there were 
no differences in ethnicity (98% vs 98% white). Fewer 
participants in the analyzed sample reported a limit-
ing long-standing illness (32% vs 42%, p < 0.001), 
but there were no baseline differences in the propor-
tion taking medication to reduce blood pressure (14% 
vs 15%), injecting insulin for diabetes (2% vs 2%), 
or following doctor’s advice to control high choles-
terol (3% vs 3%). The analyzed sample had a slightly 
higher mean weight at baseline (76.71 vs 75.18 kg, p 
< 0.001) but did not differ from the excluded partici-
pants on any other anthropometric variable. They had 
higher diastolic blood pressure (75.42 vs 74.19 mmHg, 
p < 0.001), total cholesterol (5.96 vs 5.79 mmol/l, p 
< 0.001), HDL cholesterol (1.53 vs 1.50 mmol/l, p 
= .002), LDL cholesterol (3.63 vs 3.48 mmol/l, p < 
0.001) and hemoglobin (14.40 vs 14.21 g/dl, p < 0.001) 
than the excluded participants, and lower systolic blood 
pressure (134.68 vs 136.62 mmHg, p < 0.001), fibrino-
gen (3.18 vs 3.34 g/l, p < 0.001) and CRP (1.95 vs 2.29 
mmol/l, p < 0.001). Levels of triglycerides (1.55 vs 1.58 
mmol/l) and fasting glucose (4.90 vs 4.90 mmol/l) 
did not differ significantly between the included and 
excluded participants.
The 5160 participants who provided information 
on at least one cardio-metabolic parameter at baseline 
and follow-up are henceforth referred to as the ‘full eli-
gible sample’. Of these participants, 1862 (36%) were 
free of limiting long-standing illness, were not taking 
action to reduce their cholesterol at either wave, and 
had no change between waves in use of medication for 
  hypertension or diabetes (the ‘healthy subsample’).
Demographic characteristics of the full eligible 
sample and the healthy subsample are presented in 
Table 1. In the full eligible sample, there were roughly 
equal numbers of 50–64-year-olds and over-65s (51% 
vs 49%), and slightly more women than men (56% 
vs 44%). The majority were white (98%) and mar-
ried (67%). The healthy subsample was similarly 
distributed by sex and ethnicity, but more were aged 
50–64 years (63%) and married (73%).
Table 1 also shows the proportion at baseline, follow-
up and both time points, who reported a limiting long-
standing illness, were taking action to lower cholesterol 
levels, or were taking medication for hypertension or 
diabetes. In the full eligible sample, 45% of partici-
pants reported a limiting long-standing illness at base-
line or follow-up, 2% stopped taking anti-hypertensive 
medication between baseline and follow-up, 23% 
started taking anti-hypertensive medication and 13% 
were taking medication at both waves. Just two indi-
viduals (0.04%) stopped injecting insulin for diabe-
tes, 29 (0.6%) started injecting insulin and 75 (1.5%) 
were injecting insulin at both baseline and follow-up. 
A total of 23% of participants were taking action to 
reduce their cholesterol at one or both waves.
Stability of anthropometric variables
Results of the repeated-measures ANOVAs and intra-
class correlations testing the stability of the anthropo-
metric variables are shown in Table 2. There was a small 
decrease in height over time in both samples (-0.1 cm, 
SE = 0.01), but no significant change in weight in either 
sample. BMI therefore increased slightly over time, by 
0.08 points (SE = 0.03) in the full eligible sample and 
by 0.11 points (SE = 0.04) in the healthy subsample. 
Waist circumference also increased slightly over time 
(+1.33 cm, SE = 0.07 in the full eligible sample; +1.36 
cm, SE = 0.12 in the healthy subsample).
Individuals’ positions in the distribution were 
highly stable between baseline and 4-year follow-up, 
with high intraclass correlations in both the full eli-
gible sample (ICC > 0.92) and the healthy subsample 
(ICC > 0.92).
Stability of cardio-metabolic parameters
Results of the repeated-measures ANOVAs and intra-
class correlations for the cardio-metabolic parameters 
are shown in Table 3 (untransformed variables) and 
Table 4 (log-transformed variables).
Mean changes over time were similar in the full eli-
gible sample and the healthy subsample. Systolic blood 
pressure decreased slightly in the full eligible sample 
(-0.88 mmHg, SE = 0.28) and increased slightly in 
the healthy subsample (+1.10 mmHg, SE = 0.40). Dia-
stolic blood pressure decreased in both samples (-2.09 
mmHg, SE = 0.16 in the full eligible sample; -0.61 
mmHg, SE = 0.25 in the healthy subsample). There 
were small decreases in total and LDL cholesterol 
(-0.4 mmol/l, SE = 0.02 in the full eligible sample; www.futuremedicine.com 113 future science group
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Table 1. Demographic and health-related characteristics of the full eligible sample (n = 5160) and 
healthy subsample (n = 1862) of older adults in the English Longitudinal Study of Ageing.
Characteristics Full eligible sample 
(n = 5160), n (%)
Healthy subsample† 
(n = 1862), n (%)
Age at baseline (years):    
– 50–64 2631 (51.0) 1166 (62.6)
– ≥65 2529 (49.0) 696 (37.4)
Sex:    
– Male 2278 (44.1) 865 (46.5)
– Female 2882 (55.9) 997 (53.5)
Ethnicity:    
– White 5074 (98.3) 1838 (98.7)
– Non-white 84 (1.6) 24 (1.3)
– Missing 2 (0.04) –
Marital status:    
– Married 3473 (67.3) 1356 (72.8)
– Unmarried 1687 (32.7) 506 (27.2)
Limiting long-standing illness:    
– Yes at baseline only 485 (9.4) –
– Yes at follow-up only 652 (12.6) –
– Yes at baseline and follow-up 1185 (23.0) –
– No 2836 (55.0) 1862 (100.0)
– Unknown 2 (0.04) –
Taking medication for hypertension:    
– Yes at baseline only 90 (1.7) –
– Yes at follow-up only 1192 (23.1) –
– Yes at baseline and follow-up 648 (12.6) 170 (9.1)
– No 3228 (62.6) 1692 (90.9)
– Unknown 2 (0.04) –
Taking medication for diabetes:    
– Yes at baseline only 2 (0.04) –
– Yes at follow-up only 29 (0.6) –
– Yes at baseline and follow-up 75 (1.5) 4 (0.2)
– No 5008 (97.1) 1858 (99.8)
– Unknown 46 (0.9) –
Taking action to lower cholesterol‡:    
– Yes at baseline only 37 (0.7) –
– Yes at follow-up only 1135 (22.0) –
– Yes at baseline and follow-up 101 (2.0) –
– No 3882 (75.2) 1862 (100.0)
– Unknown 5 (0.1) –
†Excluded are n = 3298 with any limiting long-standing illness, change in use of medication for hypertension or diabetes, or taking action to 
reduce cholesterol at either baseline or follow-up.
‡Baseline = following doctor advice; follow-up = taking medication.114 Biomark. Med. (2015) 9(2) future science group
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-0.2 mmol/l, SE = 0.02 in the healthy subsample), and 
small increases in HDL cholesterol (+0.02 mmol/l, SE 
= 0.004 in the full eligible sample; +0.03 mmol/l, SE 
= 0.01 in the healthy subsample). Triglyceride levels 
fell in the full eligible sample (ratio: 0.97, 95% CI: 
0.95–0.98) but did not change significantly in the 
healthy subsample (ratio: 0.99, 95% CI: 0.96–1.01). 
There were slight reductions in fasting glucose (ratio: 
0.99, 95% CI: 0.98–0.99 in the full eligible sample; 
ratio: 0.98, 95% CI: 0.97–0.99 in the healthy sub-
sample) and hemoglobin (-0.35 g/dl, SE = 0.02 in 
the full eligible sample; -0.29 g/dl, SE = 0.03 in the 
healthy subsample) in both samples, and increases in 
fibrinogen (+0.23 g/l, SE = 0.01 in the full eligible 
sample; +0.25 g/l, SE = 0.02 in the healthy subsample) 
and CRP (ratio: 1.03, 95% CI: 1.00–1.07 in the full 
eligible sample; ratio: 1.13, 95% CI: 1.07–1.19 in the 
healthy subsample).
Intraclass correlations showed the highest stability 
for HDL cholesterol in both samples (ICC = 0.81). 
Other parameters were also moderately to highly stable 
over time (ICC >0.49), although stability was some-
what lower for glucose (ICC >0.43). Total and LDL 
cholesterol appeared to be somewhat more stable in 
the healthy subsample (total cholesterol: ICC = 0.68 vs 
ICC = 0.59 in the full eligible sample; LDL cholesterol: 
ICC = 0.65 vs ICC = 0.57 in the full eligible sample), as 
was systolic blood pressure (ICC = 0.59 vs ICC = 0.50 
in the full eligible sample), but no major differences 
in stability between the samples were observed for any 
other cardio-metabolic parameters.
In addition to the repeated-measures ANOVAs and 
ICCs, we also examined the stability of cardio-met-
abolic values relative to established cut-offs (Table 5). 
The proportion of participants who were in the same 
classification at baseline and follow-up (i.e., either 
above or below the cut-off at both times) ranged from 
71% to 95% in the full eligible sample, and from 73% 
to 97% in the healthy subsample. In both samples, 
fasting glucose levels showed the most stability within 
classifications. Systolic blood pressure was the least 
stable in the full eligible sample and triglycerides were 
the least stable in the healthy subsample. Stability was 
slightly higher in the healthy subsample than the full 
eligible sample for all cardio-metabolic parameters, but 
differences were small; ranging from 0.4% for HDL 
cholesterol to 4.4% for triglycerides (mean difference 
across all variables = 2.4%).
Adjustment of correlations for attenuation
We used the method recommended by Nunnally and 
Bernstein [51], as detailed by Krueger and Schkade [52], 
Table 2. Stability of anthropometric variables in the full eligible sample (n = 5160) and healthy 
subsample (n = 1862) of older adults.
 
 
n Repeated-measures ANOVA Intraclass correlation
Baseline 
mean (SE)
Follow-up 
mean (SE)
Change 
mean (SE)
Change 
p-value
ICC (95% CI)  
p-value
Full eligible sample           
Height (cm) 4040 166.50 (0.10) 166.43 (0.10) -0.07 (0.01) <0.001 0.999 (0.999–0.999) 
<0.001
Weight (kg) 4739 77.13 (0.20) 77.12 (0.20) -0.01 (0.06) 0.863 0.957 (0.954–0.959) 
<0.001
BMI (kg/m2) 3863 27.70 (0.07) 27.78 (0.08) 0.08 (0.03) 0.003 0.941 (0.938–0.945) 
<0.001
Waist (cm) 4698 96.00 (0.17) 97.33 (0.18) 1.33 (0.07) <0.001 0.926 (0.921–0.930) 
<0.001
Healthy subsample           
Height (cm) 1569 166.77 (0.17) 166.69 (0.17) -0.08 (0.01) <0.001 0.999 (0.999–0.999) 
<0.001
Weight (kg) 1773 74.87 (0.31) 74.96 (0.32) 0.09 (0.10) 0.342 0.965 (0.961–0.968) 
<0.001
BMI (kg/m2) 1522 26.81 (0.11) 26.92 (0.12) 0.11 (0.04) 0.002 0.947 (0.941–0.952) 
<0.001
Waist (cm) 1749 93.17 (0.27) 94.53 (0.28) 1.36 (0.12) <0.001 0.928 (0.921–0.934) 
<0.001
Means at baseline, means at follow-up, and mean changes over time are mutually adjusted for age and sex.
CI: Confidence interval; ICC: Intraclass correlation coefficient; SE: Standard error.www.futuremedicine.com 115 future science group
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to estimate attenuation of the true association by mea-
surement error and short-term intra-individual vari-
ability. Separate analyses were conducted for the full 
eligible sample and the healthy subsample (Table 6). 
While there was little change in the size of correla-
tions for anthropometric variables, adjustment for 
attenuation resulted in substantial increases in the size 
of correlations between baseline and follow-up mea-
surements for many cardio-metabolic parameters. For 
example, fibrinogen correlations rose from 0.53 for the 
full eligible sample and 0.52 for the healthy subsample 
to 0.74 and 0.73, respectively. The greatest adjusted 
correlation was for hemoglobin in the healthy sub-
sample (0.98). The lowest value (0.46) was for fasting 
glucose in the full eligible sample.
Discussion
This study examined the stability of anthropometric 
and cardio-metabolic variables in a large cohort of 
English adults age ≥50 years over 4 years to determine 
the extent to which older values can be assumed to 
reflect current status.
We observed very high stability for the anthro-
pometric variables. BMI and waist circumference 
increased very slightly, and height decreased slightly 
over the 4-year follow-up period, but mean changes 
Table 3. Stability of cardio-metabolic parameters (untransformed variables) in the full eligible 
sample (n = 5160) and healthy subsample (n = 1862) of older adults.
  n Repeated-measures ANOVA Intraclass correlation
  Baseline 
mean (SE)
Follow-up 
mean (SE)
Change 
mean (SE)
Change 
p-value
ICC (95% CI)  
p-value
Full eligible sample           
Systolic BP (mmHg) 4217 134.67 (0.28) 133.79 (0.28) -0.88 (0.28) 0.002 0.496 (0.472–0.518) 
<0.001
Diastolic BP (mmHg) 4217 75.40 (0.17) 73.31 (0.17) -2.09 (0.16) <0.001 0.525 (0.503–0.547) 
<0.001
Total cholesterol 
(mmol/l)
3413 5.95 (0.02) 5.52 (0.02) -0.43 (0.02) <0.001 0.587 (0.565–0.609) 
<0.001
HDL cholesterol 
(mmol/l)
3408 1.53 (0.01) 1.55 (0.01) 0.02 (0.004) <0.001 0.809 (0.797–0.820) 
<0.001
LDL cholesterol 
(mmol/l)
3276 3.62 (0.02) 3.21 (0.02) -0.41 (0.02) <0.001 0.574 (0.550–0.596) 
<0.001
Hemoglobin (g/dl) 3328 14.47 (0.02) 14.12 (0.02) -0.35 (0.02) <0.001 0.645 (0.625–0.665) 
<0.001
Fibrinogen (g/l) 3291 3.16 (0.01) 3.39 (0.01) 0.23 (0.01) <0.001 0.533 (0.508–0.557) 
<0.001
Healthy subsample           
Systolic BP (mmHg) 1560 131.84 (0.43) 132.94 (0.45) 1.10 (0.40) 0.006 0.593 (0.560–0.624) 
<0.001
Diastolic BP (mmHg) 1560 74.83 (0.26) 74.22 (0.27) -0.61 (0.25) 0.013 0.583 (0.550–0.615) 
<0.001
Total cholesterol 
(mmol/l)
1342 6.09 (0.03) 5.90 (0.03) -0.19 (0.02) <0.001 0.683 (0.653–0.710) 
<0.001
HDL cholesterol 
(mmol/l)
1338 1.57 (0.01) 1.60 (0.01) 0.03 (0.01) <0.001 0.814 (0.795–0.832) 
<0.001
LDL cholesterol 
(mmol/l)
1296 3.77 (0.03) 3.56 (0.03) -0.21 (0.02) <0.001 0.653 (0.620–0.683) 
<0.001
Hemoglobin (g/dl) 1301 14.55 (0.03) 14.26 (0.03) -0.29 (0.03) <0.001 0.679 (0.649–0.707) 
<0.001
Fibrinogen (g/l) 1298 3.09 (0.02) 3.34 (0.02) 0.25 (0.02) <0.001 0.524 (0.484–0.563) 
<0.001
BP: Blood pressure; ICC: Intraclass correlation coefficient; SE: Standard error.
Means at baseline, means at follow-up, and mean changes over time are mutually adjusted for age and sex.116 Biomark. Med. (2015) 9(2) future science group
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were less than 2% of the baseline value, and baseline 
and follow-up measurements were highly correlated. 
The majority of previous research into anthropometric 
change over time has looked across populations using 
series of cross-sectional cohorts, which typically show 
substantial increases in weight, BMI, and waist cir-
cumference over time [58–62]. There is less evidence on 
within-individual change from longitudinal analyses, 
although what has been published is consistent with 
the present results. For example, a population study 
of Finnish adults who were followed over an average 
of 5.7 years (range: 4–7 years), and one of Australian 
adults followed over 5 years, both found that individ-
ual changes in weight were small, with the majority of 
participants maintaining their weight within 5 kg of 
their initial weight [63,64].
Cardio-metabolic parameters were more variable 
over time than anthropometric measurements. Each 
of the 10 cardio-metabolic variables we examined 
changed significantly from baseline to follow-up, with 
increases in HDL cholesterol, fibrinogen and CRP, 
and decreases in systolic and diastolic blood pressure, 
total cholesterol, LDL cholesterol, triglycerides, fasting 
glucose and hemoglobin. However, despite changes in 
the means over time, the majority of participants had 
consistently high or low levels of each parameter at the 
two times, and the intra-individual correlations were 
moderate to high. These results confirm the findings of 
previous studies with smaller samples [21–26,28–33,35–38] 
or shorter follow-up periods [21,23–25,31,33], and are con-
sistent with two large-scale studies of CRP [27,34].
Inevitably, the observed association between two 
measurements of a variable is attenuated relative 
to its ‘true’ value by errors at each time of measure-
ment, which include errors related to sample collec-
tion, processing, storage and laboratory analyses [65]. 
We therefore used existing data on the extent of error 
of measurement as a basis for correcting for attenua-
tion. In the present study, the stability of the anthro-
pometric measurements was so high that correcting for 
attenuation had little effect. However, correcting for 
attenuation greatly increased the size of the correla-
tions between baseline and follow-up measurements of 
many of the cardio-metabolic parameters.
In the full eligible sample (available data at both 
times), the majority (64%) had some health charac-
teristics that could be expected to affect the stability 
of either anthropometric or cardio-metabolic markers. 
We therefore repeated the analyses excluding individu-
als with long-standing limiting illness at either time, 
taking action to manage raised cholesterol at either 
time, and change in treatment of hypertension or dia-
betes between times, to create a ‘healthy’ subsample. 
On the whole, the findings in the healthy subsample 
were very similar to the full eligible sample, except 
that systolic blood pressure and levels of total and LDL 
Table 4. Stability of cardio-metabolic parameters (log-transformed variables) in the full eligible sample (n = 5160) and 
healthy subsample (n = 1862) of older adults.
  n Repeated-measures ANOVA Intraclass correlation
  Baseline 
geometric mean 
(95% CI)
Follow-up 
geometric mean 
(95% CI)
Baseline to 
follow-up ratio 
(95% CI)
Change 
p-value
ICC (95% CI)  
p-value
Full eligible sample           
Triglycerides (mmol/l) 3413 1.55 (1.52–1.58) 1.50 (1.48–1.52) 0.97 (0.95–0.98) <0.001 0.611 (0.590–0.632) 
<0.001
Fasting glucose (mmol/l) 1503 4.91 (4.88–4.93) 4.84 (4.81–4.86) 0.99 (0.98–0.99) <0.001 0.430 (0.388–0.471) 
<0.001
CRP (mmol/l) 3410 1.89 (1.82–1.96) 1.95 (1.88–2.02) 1.03 (1.00–1.07) 0.041 0.629 (0.608–0.649) 
<0.001
Healthy subsample           
Triglycerides (mmol/l) 1342 1.45 (1.41–1.49) 1.43 (1.39–1.47) 0.99 (0.96–1.01) 0.328 0.603 (0.568–0.636) 
<0.001
Fasting glucose (mmol/l) 671 4.88 (4.84–4.92) 4.81 (4.76–4.84) 0.98 (0.97–0.99) 0.001 0.438 (0.375–0.497) 
<0.001
CRP (mmol/l) 1342 1.54 (1.45–1.63) 1.74 (1.64–1.85) 1.13 (1.07–1.19) <0.001 0.626 (0.593–0.658) 
<0.001
Means at baseline, means at follow-up, and the baseline to follow-up ratio are mutually adjusted for age and sex.
Data were log-transformed for analysis. Geometric means and 95% CI (anti-logs) are presented in the table, and ratio of change with 95% CI.
Note: difference between logs = log of ratio, therefore: log (x) - log (y) = log (x/y).
ICC: Intraclass correlation coefficient.www.futuremedicine.com 117 future science group
Four-year stability of anthropometric & cardio-metabolic parameters in a prospective cohort of older adults    Research Article
cholesterol were more stable in the healthy subsample; 
most likely due to the exclusion of individuals chang-
ing their treatment between baseline and follow-up. 
There were no notable differences between samples 
in the stability of fasting glucose levels; but very few 
participants changed their diabetic treatment (n = 31, 
0.6% of the full eligible sample). There were also no 
notable differences in the stability of inflammatory 
markers such as CRP or fibrinogen, despite 22% of the 
full eligible sample reporting a change in limiting long-
standing illness from baseline to follow-up. However, 
previous research has indicated that the most common 
self-reported limiting long-standing illnesses among 
older adults are respiratory and musculoskeletal dis-
eases, mental health problems and vision problems [66], 
which might explain why excluding these individuals 
did not have a marked effect on the stability of most 
cardio-metabolic parameters.
The present study is subject to several limitations. 
The findings cannot be assumed to apply to younger 
adults. Results might differ in specific patient groups, 
such as those with diabetes or coronary heart disease. 
The ‘healthy’ subsample excluded cases with change 
in medication for hypertension and diabetes, but not 
changes in other factors that might be expected to 
affect cardio-metabolic parameters, such as weight, 
diet, smoking, alcohol, or physical activity [67–71]. It also 
did not take into account use of hormone replacement 
therapy in women, which could affect the stability of 
some of the markers (e.g., CRP) [72], and although it 
excluded participants with a change in use of insulin 
for diabetes, it did not consider changes in use of oral 
hypoglycemic agents which would also have influenced 
glucose levels. However, applying stricter exclusion 
criteria would likely have only served to increase the 
already high estimates of stability. Another important 
limitation is that follow-up data were not available for 
all individuals who provided data at baseline. Com-
pared to those who only had data at baseline, the ana-
lyzed sample was younger and healthier – consistent 
with findings on retention in other longitudinal stud-
ies [73]; so results may not be population-representative. 
In addition, there were missing data among the ana-
lyzed sample for individual markers, which may have 
resulted in a bias toward greater stability. For example, 
reasons for missing height and weight data included 
the participant being confined to bed or otherwise ill 
or in pain; factors likely to be associated with energy 
imbalance and resultant loss or gain of body weight. 
There were several exclusion criteria for blood samples, 
such as having a clotting or bleeding disorder, which 
might have affected the estimates of stability in blood 
markers. Bias may be even more pronounced for glu-
cose results, because fasting blood samples were not 
obtained from >80-year-olds, diabetics, or participants 
who had ever reported a fit, were frail, or seemed unwell. 
Moreover, assessment of changes in glucose over time 
is limited by the use of a single fasting plasma glucose 
measurement; more reliable estimates might have been 
obtained by using glycated hemoglobin, which is sub-
ject to less fluctuation but still changes over time. The 
use of non-fasting triglyceride measurements is also 
likely to have affected estimates of stability.
Nonetheless, despite these numerous limitations, the 
results of this study provide useful benchmark data on 
typical changes in anthropometric and cardio-metabolic 
Table 5. Stability of cardio-metabolic parameters within clinical classifications in the full eligible sample (n = 5160) 
and healthy subsample (n = 1862) of older adults.
Cardio-metabolic 
parameters 
Cut-off Full eligible sample (n = 5160) Healthy subsample (n = 1862)
n  % above 
cut-off at 
baseline
% above 
cut-off at 
follow-up
% stable n  % above 
cut-off at 
baseline
% above 
cut-off at 
follow-up
% stable
Systolic BP ≥140 mmHg 4217 35.7 34.0 70.5 1560 26.6 30.3 76.3
Diastolic BP ≥90 mmHg 4217  9.2 6.8 89.1 1560 7.0 7.5 90.8
Total cholesterol ≥240 mg/dl 3413 39.1 28.3 74.2 1342 42.5 37.8 77.6
HDL cholesterol ≥60 mg/dl 3408 44.1 45.7 82.2 1338 48.1 50.9 82.6
LDL cholesterol ≥160 mg/dl 3276 29.4 19.4 76.3 1296 32.6 26.7 76.3
Triglycerides ≥1.7 mmol/l 3413 43.4 40.7 71.9 1342 38.1 36.8 73.1
Fasting glucose ≥6.1 mmol/l 1503  5.6  4.9 95.1  671  2.7  2.4 97.2
Hemoglobin ≥12.5 g/dl 3328 93.5 90.0 90.8 1301 95.4 94.6 93.9
Fibrinogen ≥3.6 g/l 3291 25.0 36.1 72.9 1298 19.6 29.3 76.0
CRP ≥3 mmol/l 3410 34.5 34.7 76.0 1342 25.4 28.4 78.8
Stable = values in the same classification at baseline and follow-up (i.e., low at baseline and low at follow-up or high at baseline and high at follow-up).118 Biomark. Med. (2015) 9(2) future science group
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variables over time in the general population. To our 
knowledge, it is the first study to explicitly compare 
changes in these markers in healthy individuals to pop-
ulation-wide changes, and the first to address the impact 
of measurement error, improving the accuracy of  stability 
estimates. The large sample size is also a strength.
Conclusion & future perspective
The present findings showed that changes in most 
anthropometric and cardio-metabolic variables over a 
period of 4 years were small, and values were generally 
highly correlated over time. In studies where it is not pos-
sible to obtain recent measures, values from several years 
before are likely to be a good proxy for analyses of asso-
ciations with health outcomes. It is important to keep in 
mind that some variables were more stable than others 
and the limitations to the reliability such as time of day 
variation, non-fasting status and lack of control for other 
medication; although these would likely have increased 
the correlations over time. The use of older measure-
ments of anthropometric and cardio-metabolic status 
where more recent data are not available will widen the 
scope of large-scale epidemiological studies to examine 
associations with chronic diseases in the future.
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